AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Eikon Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00T0XRJ84
7.26▼ 0.98 (-11.89%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
8.24
Day's Range
7.20 – 8.07
52-Week Range
6.45 – 17.40
Volume
318.0K
Avg Volume
588.2K
Share Statistics
Shares Outstanding
Employees
384
Exchange
XNAS
Listed
2026-02-05
Share count as of August 3, 2026

Eikon Therapeutics, Inc. Common Stock (EIKN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Eikon Therapeutics, Inc. Common Stock (EIKN)
What is Eikon Therapeutics, Inc. Common Stock's Market Cap?
Eikon Therapeutics, Inc. Common Stock's Market Cap is $393.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · EIKNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income (expense), net
Other income (expense), net
Net loss and comprehensive loss
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted